Viral infections in prostate carcinogenesis: literature review

Cover Page

Cite item

Full Text

Abstract

Prostate cancer is one of the most common malignant diseases in men. Viral infections can be risk factors for prostate carcinogenesis. Based on the literature review, an assumption can be made about the pathogenetic role of viral infections in prostate carcinogenesis. Further study of this problem is required, the solution of which can make a great contribution to the diagnosis and prevention of prostate cancer

About the authors

A. A. Kamalov

Medical Research and Education Center, M.V. Lomonosov Moscow State University; Department of Urology and Andrology, Faculty of Fundamental Medicine, M.V. Lomonosov Moscow State University; City Clinical Hospital No. 31, Moscow Healthcare Department

ORCID iD: 0000-0003-4251-7545

Build. 10, 27 Lomonosovskiy Prospekt, Moscow 119192; 1 Leninskie Gory, Moscow 119991; 42 Lobachevskogo St., Moscow 119415

Russian Federation

L. M. Mikhaleva

City Clinical Hospital No. 31, Moscow Healthcare Department; A.P. Avtsyn Research Institute of Human Morphology, B.V. Petrovsky Russian Scientific Center of Surgery

ORCID iD: 0000-0003-2052-914X

42 Lobachevskogo St., Moscow 119415; 3 Tsyrupy St., Moscow 117418

Russian Federation

V. B. Matveev

Medical Research and Education Center, M.V. Lomonosov Moscow State University; Department of Urology and Andrology, Faculty of Fundamental Medicine, M.V. Lomonosov Moscow State University; N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0001-7748-9527

Build. 10, 27 Lomonosovskiy Prospekt, Moscow 119192; 1 Leninskie Gory, Moscow 1199914; 24 Kashirskoe Shosse, Moscow 115478

Russian Federation

V. K. Karpov

Medical Research and Education Center, M.V. Lomonosov Moscow State University; Department of Urology and Andrology, Faculty of Fundamental Medicine, M.V. Lomonosov Moscow State University; City Clinical Hospital No. 31, Moscow Healthcare Department

ORCID iD: 0000-0001-7644-4263

Build. 10, 27 Lomonosovskiy Prospekt, Moscow 119192; 1 Leninskie Gory, Moscow 119991; 42 Lobachevskogo St., Moscow 119415

Russian Federation

D. A. Okhobotov

Medical Research and Education Center, M.V. Lomonosov Moscow State University; Department of Urology and Andrology, Faculty of Fundamental Medicine, M.V. Lomonosov Moscow State University

ORCID iD: 0000-0002-6768-9004

Build. 10, 27 Lomonosovskiy Prospekt, Moscow 119192; 1 Leninskie Gory, Moscow 119991

Russian Federation

O. A. Osmanov

Medical Research and Education Center, M.V. Lomonosov Moscow State University; City Clinical Hospital No. 31, Moscow Healthcare Department

Author for correspondence.
Email: omar_osmanov07@mail.ru
ORCID iD: 0000-0003-1453-9771

Build. 10, 27 Lomonosovskiy Prospekt, Moscow 119192; 42 Lobachevskogo St., Moscow 119415

Russian Federation

E. P. Akopyan

City Clinical Hospital No. 31, Moscow Healthcare Department; A.P. Avtsyn Research Institute of Human Morphology, B.V. Petrovsky Russian Scientific Center of Surgery

ORCID iD: 0000-0002-1826-9169

42 Lobachevskogo St., Moscow 119415; 3 Tsyrupy St., Moscow 117418

Russian Federation

B. M. Shaparov

Medical Research and Education Center, M.V. Lomonosov Moscow State University; Department of Urology and Andrology, Faculty of Fundamental Medicine, M.V. Lomonosov Moscow State University

ORCID iD: 0000-0002-0232-1567

Build. 10, 27 Lomonosovskiy Prospekt, Moscow 119192; 1 Leninskie Gory, Moscow 119991

Russian Federation

References

  1. Ferlay J., Ervik M., Lam F. et al. Global cancer observatory: cancer today. International Agency for Research on Cancer, Lyon, France, 2018. Available at: https://gco.iarc.fr/today.
  2. Culp M.B.B., Soerjomataram I., Efstathiou J.A. et al. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 2020;77(1):38– 52. doi: 10.1016/j.eururo.2019.08.005
  3. Malignant tumors in Russia in 2019 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2020. 252 p. (In Russ.).
  4. Delongchamps N.B., Singh A., Haas G.P. The role of prevalence in the diagnosis of prostate cancer. Cancer Control 2006;13(3):158–68. doi: 10.1177/107327480601300302
  5. Siraziev А.М., Khasanova G.R., Ulyanin M.Yu. Risk factors of prostate cancer. Meditsinskiy al’manah = Medical Almanac 2019; 3–4(60):110–4. (In Russ.). doi: 10.21145/2499-9954-2019-3-110-114
  6. Rao D., Yu H., Bai Y. et al. Does nightshift work increase the risk of prostate cancer? A systematic review and metaanalysis. Onco Targets Ther 2015;8:2817–26. doi: 10.2147/OTT.S89769
  7. Chen C.J., Hsu W.L., Yang H.I. et al. Epidemiology of virus infection and human cancer. Recent Results Cancer Res 2014;193:11–32. doi: 10.1007/978-3-642-38965-8_2
  8. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002;420(6917):860–7. doi: 10.1038/nature01322
  9. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008;454(7203):436–44. doi: 10.1038/nature07205
  10. Sudenga S.L., Ingles D.J., Pierce Campbell C.M. et al. Genital human papillomavirus infection progression to external genital lesions: the HIM study. Eur Urol 2016;69(1):166–73. doi: 10.1016/j.eururo.2015.05.032
  11. Bouwes Bavinck J.N., Neale R.E., Abeni D. et al. Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma. Cancer Res 2010;70(23):9777–86. doi: 10.1158/0008-5472.CAN-10-0352
  12. Volgareva G.M., Ermilova V.D. Detection of human papillomavirus type 18 oncogen E7 in patients with prostate cancer. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2019;18(1):37–41. (In Russ.). doi: 10.17650/1726-9784-2019-18-1-37-41
  13. McNicol P.J., Dodd J.G. Detection of human papillomavirus DNA in prostate gland tissue by using the polymerase chain reaction amplification assay. J Clin Microbiol 1990;28(3):409–12. doi: 10.1128/JCM.28.3.409-412.1990
  14. Taverna G., Pedretti E., Di Caro G. et al. Inflammation and prostate cancer: friends or foe? Inflamm Res 2015;64(5):275–86. doi: 10.1007/s00011-015-0812-2
  15. Dávila-Rodríguez M.I., Ignacio Morales C.V., Aragón Tovar A.R. et al. Human papilloma virus detection by INNOLiPA HPV in prostate tissue from men of northeast Mexico. Asian Pac J Cancer Prev 2016;17(11):4863–5. doi: 10.22034/APJCP.2016.17.11.4863
  16. Atashafrooz F., Rokhbakhsh-Zamin F. Frequency and type distribution of human papilloma virus in patients with prostate cancer, Kerman, southeast of Iran. Asian Pac J Cancer Prev 2016;17(8):3953–8.
  17. Huang L., Wu M.G., He J. et al. Correlation of high-risk HPV 16/18 infections with prostate cancer. Zhonghua Nan Ke Xue 2016;22(6):501–5.
  18. Glenn W.K., Ngan C.C., Amos T.G. et al. High risk human papilloma viruses (HPVs) are present in benign prostate tissues before development of HPV associated prostate cancer. Infect Agent Cancer 2017;12:46. doi: 10.1186/s13027-017-0157-2
  19. Medel-Flores O., Valenzuela-Rodríguez V.A., Ocadiz-Delgado R. et al. Association between HPV infection and prostate cancer in a Mexican population. Genet Mol Biol 2018;41(4):781–9. doi: 10.1590/1678-4685-GMB-2017-0331
  20. Volgareva G.M., Ermilova V.D., Khachaturyan A.V. et al. Detection of human papillomavirus type 16 onco- gen E7 in surgical materials from Russian prostate cancer patients. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2017;16(3):59–62. (In Russ.). doi: 10.17650/1726-9784-2017-16-3-59-62
  21. Moghoofei M., Keshavarz M., Ghorbani S. et al. Association between human papillomavirus infection and prostate cancer: a global systematic review and metaanalysis. Asia Pac J Clin Oncol 2019;15(5):e59–67. doi: 10.1111/ajco.13124
  22. Russo G.I., Calogero A.E., Condorelli R.A. et al. Human papillomavirus and risk of prostate cancer: a systematic review and meta-analysis. Aging Male 2020;23(2): 132–8. doi: 10.1080/13685538.2018.1455178
  23. Fatemipour M., Sadri Nahand J., Ebadi Fard Azar M. et al. Human papillomavirus and prostate cancer: the role of viral expressed proteins in the inhibition of anoikis and induction of metastasis. Microb Pathog 2021;152:104576. doi: 10.1016/j.micpath.2020.104576
  24. Lawson J.S., Glenn W.K. Multiple pathogens and prostate cancer. Infect Agent Cancer 2022;17(1):23. doi: 10.1186/s13027-022-00427-1
  25. Khatami A., Nahand J.S., Kiani S.J. et al. Human papilloma virus (HPV) and prostate cancer (PCa): the potential role of HPV gene expression and selected cellular MiRNAs in PCa development. Microb Pathog 2022;166:105503. doi: 10.1016/j.micpath.2022.105503
  26. Groom H.C.T., Warren A.Y., Neal D.E., Bishop K.N. No evidence for infection of UK prostate cancer patients with XMRV, BK virus, Trichomonas vaginalis or human papilloma viruses. PLoS One 2012;7(3):e34221. doi: 10.1371/journal.pone.0034221
  27. Aydin M., Bozkurt A., Cikman A. et al. Lack of evidence of HPV etiology of prostate cancer following radical surgery and higher frequency of the Arg/Pro genotype in Turkish men with prostate cancer. Int Braz J Urol 2017;43(1):36–46. doi: 10.1590/S1677-5538.IBJU.2015.0429
  28. Tachezy R., Hrbacek J., Heracek J. et al. HPV persistence and its oncogenic role in prostate tumors. J Med Virol 2012;84(10):1636–45. doi: 10.1002/jmv.23367
  29. Sutcliffe S., Viscidi R.P., Till C. et al. Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2010;19(2):614–8. doi: 10.1158/1055-9965.EPI-09-1080
  30. Semenova T.B., Stoyanov V.B. Herpetic infection of the genitourinary system in men. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2001;(13):568. (In Russ.).
  31. Lekstron-Himes J.A., Dale J.K., Kingma D.W. Periodic illness assotiated with Epstein–Barr virus infection. Clin Infect 2009;22(1):22–7. doi: 10.1093/clinids/22.1.22
  32. Andabekov T.T. Influence of cytomegalovirus infection on the clinical course of prostate cancer. Dis. … candidate of medical sciences. Saint Petersburg, 2010. (In Russ.).
  33. Thomas F., Elguero E., Brodeur J. et al. Herpes simplex virus type 2 and cancer: a medical geography approach. Infect Genet Evol 2011;11(6):1239–42. doi: 10.1016/j.meegid.2011.04.009
  34. Samsonov R.B., Klochkova T.G., Evtushenko V.I. Infection of the prostate tissue of the prostate cancer patients by the Herpesviridae and HPV. Voprosy onkologii = Issues of Oncology 2012;58(6):795–9. (In Russ.).
  35. Ge X., Wang X., Shen P. Herpes simplex virus type 2 or human herpesvirus 8 infection and prostate cancer risk: a metaanalysis. Biomed Rep 2013;1(3):433–9. doi: 10.3892/br.2013.82
  36. Mygatt J.G., Singhal A., Sukumar G. et al. Oncogenic herpesvirus HHV-8 promotes androgen-independent prostate cancer growth. Cancer Res 2013;73(18):5695–708. doi: 10.1158/0008-5472.CAN-12-4196
  37. Tsao Y.H., Hsieh C.J., Juan Y.S. et al. Herpes zoster and the subsequent risk of prostate cancer in an Asian population: a nationwide population-based cohort study. Medicine (Baltimore) 2020;99(40):e22441. doi: 10.1097/MD.0000000000022441
  38. Jenkins F.J., Minas T.Z., Tang W. et al. Human herpesvirus 8 infection is associated with prostate cancer among IFNL4-ΔG carriers. Prostate Cancer Prostatic Dis 2022. doi: 10.1038/s41391-022-00546-1
  39. Nahand J.S., Khanaliha K., Mirzaei H. et al. Possible role of HPV/EBV coinfection in anoikis resistance and development in prostate cancer. BMC Cancer 2021;21(1): 926. doi: 10.1186/s12885-021-08658-y
  40. Leskinen M.J., Vainionp R., Syrjnen S. et al. Herpes simplex virus, cytomegalovirus, and papillomavirus DNA are not found in patients with chronic pelvic pain syndrome undergoing radical prostatectomy for localized prostate cancer. Urology 2003;61(2):397–401. doi: 10.1016/s0090-4295(02)02166-0
  41. Korodi Z., Wang X., Tedeschi R. et al. No serological evidence of association between prostate cancer and infection with herpes simplex virus type 2 or human herpesvirus type 8: a nested case-control study. J Infect Dis 2005;191(12):2008–11. doi: 10.1086/430354
  42. Sutcliffe S., Till C., Gaydos C.A. et al. Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. Cancer Causes Control 2012;23(9):1511–8. doi: 10.1007/s10552-012-0028-5

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.